A study by the Evernorth Research Institute looking at national prescription drug use trends found GLP-1 use between 2023-2024 rose 84.6% in Gen Alpha (ages 14 and younger). The age group was ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

The pioneering Yellow Card Biobank, launched by the Medicines and Healthcare products Regulatory Agency (MHRA) and Genomics ...

A new study is showing the effectiveness of GLP-1 medication, commonly referred to as weight loss drugs, and how they stack ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

In a matched group of more than 170,000 adults, those treated with GLP-1 agonists had a lower risk of developing an obesity-related cancer over a median follow-up of about 4 years when compared ...

The prevalence of U.S. adults without diabetes who filled a GLP-1 receptor agonist prescription rose from 0.1% in 2018 to 0.4% in 2022. As a result, annual spending jumped from $1.6 billion to $5. ...

Please use one of the following formats to cite this article in your essay, paper or report: APA. Sai Lomte, Tarun. (2025, May 14). GLP-1 weight loss drugs leave users low on key nutrients, study ...

Patients hospitalised for acute pancreatitis after using GLP-1 receptor agonists are being recruited for a Yellow Card ...

This new study was prospective, meaning the researchers proactively tracked how people’s alcohol use changed after starting GLP-1 therapy (many past similar studies were retrospective, which ...

A recent study, published in JAMA Ophthalmology and conducted by University of Toronto researchers, found that diabetes patients who use GLP-1 drugs were twice as likely to develop neovascular age ...

Mouse study shows IBIO-610 alone drives an overall body weight loss of 8.9%*, and prevents weight regain following GLP-1 treatment in obese mice, results of which will be presented at ADA on ...